Mafla-España, M.A.; Torregrosa, M.D.; Beamud-Cortés, M.; Bermell-Marco, L.; Rubio-Briones, J.; Cauli, O.
Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy. Biomolecules 2023, 13, 1642.
https://doi.org/10.3390/biom13111642
AMA Style
Mafla-España MA, Torregrosa MD, Beamud-Cortés M, Bermell-Marco L, Rubio-Briones J, Cauli O.
Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy. Biomolecules. 2023; 13(11):1642.
https://doi.org/10.3390/biom13111642
Chicago/Turabian Style
Mafla-España, Mayra Alejandra, MarÃa Dolores Torregrosa, Manel Beamud-Cortés, Lorena Bermell-Marco, José Rubio-Briones, and Omar Cauli.
2023. "Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy" Biomolecules 13, no. 11: 1642.
https://doi.org/10.3390/biom13111642
APA Style
Mafla-España, M. A., Torregrosa, M. D., Beamud-Cortés, M., Bermell-Marco, L., Rubio-Briones, J., & Cauli, O.
(2023). Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy. Biomolecules, 13(11), 1642.
https://doi.org/10.3390/biom13111642
